Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: kendall harmon who wrote (30022)	12/17/1998 1:01:00 PM
From: Gravitar	Read Replies (1) \| Respond to of 119973

Immunomedics Reports Potential New Cancer Immunotherapy December 17, 1998 12:55 PM MORRIS PLAINS, N.J., Dec. 17 /PRNewswire/ -- Immunomedics, Inc. IMMU announced today the publication of experimental results in the November issue of Clinical Cancer Research, in which its proprietary humanized CEA antibody was used successfully to selectively kill human colorectal cancer cells growing in cell culture. The CEA antibody was engineered into a single-chain immunotoxin, whereby a highly toxic substance was attached to the antibody. According to the authors of this article, led by Dr. R.P. Junghans of the Harvard Institutes of Medicine at Beth Israel Deaconess Medical Center in Boston, "To our knowledge, this is the sole example of a recombinant immunotoxin against CEA to be reported to date." The toxic substance coupled to the cancer-targeting antibody as an immunotoxin is only toxic to cancer cells, thus sparing normal cells. The authors of this paper demonstrated this effect with the anti-CEA antibody fragment, selectively killing the human colorectal cancer cells expressing CEA. "Since a majority of cancers express CEA, this new therapeutic approach using immunotoxins may have significant medical and commercial opportunities," commented Immunomedics' President and CEO, Robert J. DeLuccia. "This same antibody, labeled with the therapeutic radioisotope yttrium-90, is also being evaluated in Immunomedics' clinical trials for cancer therapy," he further stated. Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to deliver radioisotopes and chemotherapeutic agents to tumors and sites of infection. The Company's first product, CEA-Scan(R) for the detection of colorectal cancer, is being marketed in the United States and Europe (approved in Canada). The Company's second diagnostic imaging product, LeukoScan(R), is being marketed in Europe for the diagnosis of osteomyelitis (bone infection). This product is presently under regulatory review by the U.S. Food and Drug Administration. Immunomedics also has several other diagnostic imaging products and two therapeutic products in clinical trials. This release, in addition to historical information, contains certain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements may involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirement/actions), competitive risks to marketed products and availability of financing and other sources of capital as well as those discussed in the Company's Annual Report on Form 10-K for the year ended June 30, 1998. Company Contact: Cynthia Sullivan, Executive Director, (973) 605-8200, ext. 109. Visit Immunomedics' web site at immunomedics.com. SOURCE Immunomedics, Inc